Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy, even as novel agents like Orgovyx (Myovant) enter the treatment algorithm. Zytiga (Janssen) and Xtandi (Pfizer / Astellas) are cornerstone treatments for metastatic castrate-resistant prostate cancer (mCRPC). The use of second-generation hormonal agents has expanded beyond mCRPC, and these drugs are being positioned for the treatment of nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer—earlier and more-lucrative treatment settings. Targeted agents in the dynamic late-phase pipeline mostly target mCRPC (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna, Array BioPharma / Roche’s ipatasertib, AstraZeneca’s capivasertib, Novartis’s 177Lu-PSMA-617), and although the mCRPC market is crowded, they will contribute to robust market growth over the 2020-2030 forecast period.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.